


GI



AB The title compds. [I; X, Y, Z = C, O, S, N; A = R1C(O)C(O), R1C(O)C(S), R1SO2, R1(E)NC(O); R1, E = H, C1-9 alkyl, C2-9 alkenyl, aryl, heteroaryl, carbocyclyl, heterocyclyl; D = bond, (substituted) C1-10 alkylene, CH:CH; R2 = CO2H, carboxylic acid isostere; n = 1-3] are prepared for treating vision disorders, improving vision, treating memory impairment, or enhancing memory performance in an animal. I bind to immunophilin FKBP12 and preferably do not have immunosuppressive activity. Affinity for FKBP12 is measured as inhibition of prolyl peptidyl cis-trans isomerase (rotamase). Thus, GPI 1046 (10 mg/kg s.c.) protected retinal ganglion cells and optic nerve axons and myelin against degeneration following retinal ischemia in rats, and protected against retinal ganglion cell death after optic nerve transection. Me 1,3-oxazolidine-4-carboxylate was condensed with Me oxalyl chloride and the product reacted with 1,1-dimethylpropylmagnesium chloride and saponification to produce 3-(3,3-dimethyl-2-oxopentanoyl)-1,3-oxazolidine-4-carboxylic acid, I [X = Z = CH2, Y = O, A = CH3CH2CMe2C(O)C(O), D = bond, R2 = CO2H, n = 1].

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:784085 CAPLUS
 DOCUMENT NUMBER: 132:18814
 TITLE: Aza-heterocyclic compounds used to treat neurological disorders and hair loss
 INVENTOR(S): Hamilton, Gregory S.; Norman, Mark H.; Wu, Yong-Qian; Li, Jia-He; Steiner, Joseph P.
 PATENT ASSIGNEE(S): Guilford Pharmaceuticals Inc., USA; Amgen, Inc.
 SOURCE: PCT Int. Appl., 106 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9962888	A1	19991209	WO 1998-US25574	19981203
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,				

10/408,276

MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2333964	AA	19991209	CA 1998-2333964	19981203
AU 9917082	A1	19991220	AU 1999-17082	19981203
ZA 9811062	A	19991220	ZA 1998-11062	19981203
BR 9815919	A	20010220	BR 1998-15919	19981203
EP 1102756	A1	20010530	EP 1998-961867	19981203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002517383	T2	20020618	JP 2000-552100	19981203
NO 2000006117	A	20010201	NO 2000-6117	20001201
BG 105013	A	20010831	BG 2000-105013	20001201
US 2002045641	A1	20020418	US 2001-776904	20010206
PRIORITY APPLN. INFO.:				US 1998-87843P P 19980603
				US 1998-204238 A3 19981203
				WO 1998-US25574 W 19981203

OTHER SOURCE(S): MARPAT 132:18814

IT 251951-49-2 251954-85-5


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(heterocyclic compds. for treatment of neurol. disorder or hair loss)

RN 251951-49-2 CAPLUS

CN 1-Imidazolidinecarboxamide, 5-cyano-N-(1-phenylethyl)-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251954-85-5 CAPLUS

CN 3-Thiazolidinecarboxamide, 4-cyano-N-(phenylmethyl)-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI